<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773119</url>
  </required_header>
  <id_info>
    <org_study_id>2312</org_study_id>
    <nct_id>NCT04773119</nct_id>
  </id_info>
  <brief_title>AF Burden and Echo-guided Persistent AF Ablation Strategy Using Either PV Isolation Alone (CLOSE Protocol) or Optimized Compartmentalization of the Left Atrium (Pseudo-maze Technique)</brief_title>
  <acronym>CLOSEMAZE</acronym>
  <official_title>AF Burden and Echo-guided Persistent AF Ablation Strategy Using Either PV Isolation Alone (CLOSE Protocol) or Optimized Compartmentalization of the Left Atrium (Pseudo-maze Technique): the CLOSEMAZE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent publications suggest that neither empirical nor individualized substrate modification&#xD;
      strategies could improve single-procedure efficacy beyond pulmonary vein (PV) isolation for&#xD;
      persistent atrial fibrillation (AF). However, persistent AF represent a broad spectrum of the&#xD;
      same disease and if PV isolation may be sufficient for some patient with self-terminated AF&#xD;
      or with a small left atrium, a more extended substrate ablation may be required for other&#xD;
      patients, for which a second procedure for atrial tachycardia (AT) recurrence is then&#xD;
      frequently needed. In addition, a lot of progress has recently been made in the field of&#xD;
      ablation techniques using contiguous and optimized ablation radiofrequency (RF) lesions and&#xD;
      also for AT mapping with promising results using repetitive but discontinuous Holter&#xD;
      monitoring.&#xD;
&#xD;
      This trial aims at&#xD;
&#xD;
        1. To objectively compare atrial tachyarrhythmia (ATA) burden &gt; 2 months before ablation&#xD;
           and after one or two 'CLOSEMAZE'-guided ablation(s) using continuous monitoring and echo&#xD;
           data as a guide for the ablation strategy during the first ablation.&#xD;
&#xD;
        2. To assess ATA burden using continuous monitoring up to 3 years after ablation.&#xD;
&#xD;
        3. To identify baseline structural and electrical properties of the atria or procedural&#xD;
           characteristics that predict 1-year and 3-year outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial tachyarrhythmia (ATA) burden before and after 'CLOSEMAZE'-guided based ablation and off anti-arrhythmic drug (AAD) therapy</measure>
    <time_frame>CLR implant to 3 year post ablation</time_frame>
    <description>ATA burden (= time that a subject experiences AF) will be monitored with continuous loop recording (CLR) from time of CLR implant until 3 years after ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial tachyarrhythmia burden after one CLOSEMAZE guided ablation</measure>
    <time_frame>3 years after ablation</time_frame>
    <description>ATA burden after first ablation documented through continuous loop recordings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial tachyarrhythmia burden after two CLOSEMAZE guided ablation</measure>
    <time_frame>3 years after ablation</time_frame>
    <description>ATA burden after two ablations documented through continuous loop recordings</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation (PVI) only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PVI with substrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI only</intervention_name>
    <description>Patients in this group receive PVI only</description>
    <arm_group_label>Pulmonary vein isolation (PVI) only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI with substrate ablation</intervention_name>
    <description>Patients in this group receive PVI as well as substrate ablation</description>
    <arm_group_label>PVI with substrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients with symptomatic persistent AF (history of continuous AF &gt; 7 days), meeting&#xD;
             following criteria at the out-patient clinic:&#xD;
&#xD;
               -  patient has AF at the time of the visit&#xD;
&#xD;
               -  AF episodes are symptomatic, and patient is drug-resistant (at least one class Ic&#xD;
                  or III), or drug-intolerant (palpitations, fatigue, dyspnea, cardiomyopathy,…)&#xD;
&#xD;
               -  If the patient has heart failure (LVEF&lt;50%), first line AF ablation (instead of&#xD;
                  amiodarone) is indicated&#xD;
&#xD;
          2. Signed Patient Informed Consent Form.&#xD;
&#xD;
          3. Age 18 years or older.&#xD;
&#xD;
          4. Able and willing to comply with all follow-up testing and requirements.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Longstanding persistent atrial fibrillation (Suspected continuous AF&gt;1 year)&#xD;
&#xD;
          2. Previous ablation for AF&#xD;
&#xD;
          3. left atrial antero-posterior diameter &gt; 55 mm (parasternal long axis view (PLAX))&#xD;
&#xD;
          4. LVEF &lt; 30% (ejection fraction)&#xD;
&#xD;
          5. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
          6. Coronary artery bypass graft within the last three months&#xD;
&#xD;
          7. Awaiting cardiac transplantation or other cardiac surgery&#xD;
&#xD;
          8. Documented left atrial thrombus on imaging&#xD;
&#xD;
          9. Diagnosed atrial myxoma&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding&#xD;
&#xD;
         11. Acute illness or active systemic infection or sepsis&#xD;
&#xD;
         12. Unstable angina&#xD;
&#xD;
         13. Uncontrolled heart failure&#xD;
&#xD;
         14. Myocardial infarction within the previous two months&#xD;
&#xD;
         15. History of blood clotting or bleeding abnormalities&#xD;
&#xD;
         16. Contraindication to anticoagulation therapy (ie, heparin or warfarin)&#xD;
&#xD;
         17. Life expectancy less than 12 months&#xD;
&#xD;
         18. Enrollment in any other study evaluating another device or drug&#xD;
&#xD;
         19. Presence of intramural thrombus, tumor or other abnormality that precludes catheter&#xD;
             introduction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien Knecht, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Jan AV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sébastien Knecht, MD, PhD</last_name>
    <phone>+32 50 45 26 70</phone>
    <email>sebastien.knecht@azsintjan.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Lycke, MSc, PhD</last_name>
    <phone>+32 50 45 32 93</phone>
    <email>michelle.lycke@azsintjan.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <state>West-Flanders</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Lycke, MSc, PhD</last_name>
      <phone>+32 50 45 32 93</phone>
      <email>michelle.lycke@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Sébastien Knecht, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Sebastien Knecht</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

